RxDoctor Payments Data

Patricia Reposa, APRN

Clinical Nurse Specialist · Warwick, RINPI 1619059425

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 401 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations.

$7,378in general payments, 2019–2025

Across 401 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$868
  • AbbVie$783
  • Teva Pharmaceuticals USA, Inc.$748
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$724
  • Alkermes, Inc.$632
  • Supernus Pharmaceuticals, Inc.$577
  • plus $3K from 18 others

What the payments were for

  • Food & beverage$7,366100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical nurse specialist providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$8,494
Medicare patients
23
Services billed
98

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide17$9,834
SaphrisAsenapine Maleate12$7,012
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine33$1,457
Aripiprazole27$791
Nefazodone Hcl11$777
Mirtazapine28$732
Quetiapine Fumarate33$560
Bupropion XlBupropion Hcl16$552
Lamotrigine49$547
Clonazepam95$521
Duloxetine Hcl19$420
Venlafaxine Hcl ErVenlafaxine Hcl35$377
Escitalopram Oxalate31$336
Hydroxyzine Hcl17$290
Sertraline Hcl28$235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$363$9,83417 claims
AbbVieSaphris$783$7,01212 claims
Almatica Pharma LLCSertraline Hcl$129$23528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical nurse specialist providers in Rhode Islandon file to place this against a meaningful peer group, so we don't.

Other clinical nurse specialist in Warwick

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →